PDCD1 and cancer: Gaining a more comprehensive understanding of the mechanisms governing resistance to PD‐1/PD‐L1 blockade and identifying approaches to counteract immunotherapy resistance are urgent priorities for the precision immunotherapy of cancer [47, 48].